RxDoctor Payments DataLook up a doctor →

Philip Odonnell, MD

Cardiovascular Disease · Winchester, VANPI 1871596924

Payments from drug & device makers

$4,617,902in general payments, 2019–2025

Across 4,431 payments — averaging $1042.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$3.2M
  • Amgen$428K
  • Regeneron$145K
  • Boehringer Ingelheim$139K
  • Janssen Research & Development, LLC$136K
  • Novartis$115K
  • plus $410K from 11 others

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,617,902 in reported general payments places this provider in the 95th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$164,094
Medicare patients
765
Services billed
2,347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →